Mendus

Focus: Mendus is a Swedish cell therapy biotech focused on immuno-oncology, leveraging dendritic cell and other cellular approaches to treat solid and hematologic malignancies. Founded in 2022 and publicly listed, the company is in early clinical development with a portfolio spanning renal cell carcinoma, ovarian cancer, and AML.

Oncology Gene Therapy Cell Therapy

Profile data last refreshed Yesterday · AI intelligence enriched 2w ago

Funding Stage

PUBLIC

Open Jobs

About Mendus

AI assessmentNot Hiring

No open roles listed right now. Follow Mendus to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

1/9 — Limited

Company HealthSolid

Pipeline

Early-stage

8 total

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Pipeline & Clinical Trials

ilixadencel

Carcinoma, Squamous Cell of Head and Neck

PHASE_1

Clinical Trials (1)

NCT03735290A Study to Evaluate the Safety and Effectiveness of ILIxadencel Administered Into Tumors in Combination With Checkpoint Inhibitor (CPI) in Patients With ADvanced Cancer

Phase 1

Help build intelligence for Mendus

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Entry into high-conviction cell therapy space at ground-level stage with multiple shots on goal (8 pipeline programs across 4 drugs)
Public company status provides equity transparency and liquidity vs. private biotech, reducing exit risk
Focus on immuno-oncology addresses major unmet need with regulatory tailwinds for cell therapies

Watch Out For

Zero active job postings signals minimal hiring despite public status—likely very early-stage team or post-IPO contraction
All pipeline programs in Phase 1–2 with no marketed products means no revenue, no cash flow, and 5+ years to potential approval
Missing data on employee count, funding, R&D spend, and cash position creates opaqueness on runway and financial stability

Generated by Claude from Mendus's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

Intuvax

Gastrointestinal Stromal Tumor

PHASE_1

Clinical Trials (1)

NCT02686944A Study to Evaluate the Safety of Intuvax Administered Intra-tumorally in Patients With Gastrointestinal Stromal Tumors

Phase 1

COMBIG-DC

Hepatocellular Carcinoma

PHASE_1

Clinical Trials (1)

NCT01974661Phase I Safety Study of Dendritic Cell Vaccine to Treat Patients With Hepatocellular Carcinoma

Phase 1

Combig-DC

Metastatic Renal Cell Carcinoma

PHASE_1

Clinical Trials (1)

NCT01525017A Clinical Study to Evaluate Safety and Immunologic Response of COMBIG-DC, in Patients With Metastatic Kidney Cancer

Phase 1

DCP-001

Ovarian Cancer

PHASE_1

Clinical Trials (1)

NCT04739527Phase 1 Study to Evaluate the Safety, Feasibility and Immunogenicity of an Allogeneic, Cell-based Vaccine (DCP-001) in High Grade Serous Ovarian Cancer Patients After Primary Treatment

Phase 1

DCP-001

Acute Myeloid Leukemia (AML)

PHASE_1_2

Clinical Trials (1)

NCT01373515Leukemic Dendritic Cell Vaccination in Patients With Acute Myeloid Leukemia

Phase 1/2

Intuvax

Renal Cell Carcinoma, Metastatic

PHASE_2

Clinical Trials (1)

NCT02432846Intratumoral Vaccination With Intuvax Pre-nephrectomy Followed by Sunitinib Post-nephrectomy vs Sunitinib Post-nephrectomy in Newly Diagnosed Metastatic Renal Cell Carcinoma (mRCC)

Phase 2

DCP-001

Acute Myeloid Leukemia in Remission

PHASE_2

Clinical Trials (1)

NCT03697707Efficacy and Safety of Immunotherapy With Allogeneic Dendritic Cells, DCP-001, in Patients With Acute Myeloid Leukaemia

Phase 2